Third-generation CAR T cell therapy targeting relapsed or refractory CD19+lymphoid disease (HD-CAR-1)

被引：0
|
作者：
Schubert, M. -L. [1 ]
Schmitt, A. [1 ]
Neuber, B. [1 ]
Hueckelhoven-Krauss, A. [1 ]
Kunz, A. [1 ]
Wang, L. [1 ]
Gern, U. [1 ]
Michels, B. [1 ]
Sellner, L. [1 ]
Hofmann, S. [1 ]
Mueller-Tidow, C. [1 ]
Dreger, P. [1 ]
Schmitt, M. [1 ]
机构：
[1] Univ Klinikum Heidelberg, Med Klin 5, Heidelberg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V840
引用
收藏
页码：236 / 236
页数：1
相关论文
共 50 条
  • [21] CAR T-cell therapy for relapsed or refractory multiple myeloma
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (06): : E297 - E297
  • [22] A phase 1 trial of TLR2-costimulated third-generation anti-CD19 CAR T-cells for relapsed/refractory B non-Hodgkin lymphomas
    Weinkove, Robert
    George, Philip
    Fyfe, Robbie
    Nouri, Yasmin
    Dasyam, Nathaniel
    Ostapowicz, Tess
    Mester, Brigitta
    Giunti, Giulia
    Perera, Travis
    Jina, Hayden
    D'Souza, Alwyn
    Perret, Rachel
    Li, Peng
    Hermans, Ian
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 8 - 9
  • [23] Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma
    Jin, Zhen
    Xiang, Rufang
    Qing, Kai
    Li, Dan
    Liu, Zhao
    Li, Xiaoyang
    Zhu, Hongming
    Zhang, Yunxiang
    Wang, Lining
    Xue, Kai
    Liu, Han
    Xu, Zizhen
    Wang, Yingxiao
    Li, Junmin
    CELLULAR ONCOLOGY, 2023, 46 (04) : 1143 - 1157
  • [24] Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma
    Zhen Jin
    Rufang Xiang
    Kai Qing
    Dan Li
    Zhao Liu
    Xiaoyang Li
    Hongming Zhu
    Yunxiang Zhang
    Lining Wang
    Kai Xue
    Han Liu
    Zizhen Xu
    Yingxiao Wang
    Junmin Li
    Cellular Oncology, 2023, 46 : 1143 - 1157
  • [25] First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
    Korell, Felix
    Schoenland, Stefan
    Schmitt, Anita
    Jansen, Madelaine
    Farid, Kiavasch
    Mueller-Tidow, Carsten
    Dreger, Peter
    Schmitt, Michael
    Hegenbart, Ute
    BIOMARKER RESEARCH, 2023, 11 (01)
  • [26] First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
    Felix Korell
    Stefan Schönland
    Anita Schmitt
    Madelaine Jansen
    Kiavasch Farid
    Carsten Müller-Tidow
    Peter Dreger
    Michael Schmitt
    Ute Hegenbart
    Biomarker Research, 11
  • [27] Clinical Outcomes of CLL Patients with Relapsed or Refractory Disease after CD19-Specific CAR-T Therapy
    Shadman, Mazyar
    Gauthier, Jordan
    Khajavian, Sirin
    Hirayama, Alexandre V.
    Lynch, Ryan C.
    Smith, Stephen D.
    Ujjani, Chaitra S.
    Chow, Victor
    Kiem, Hans-Peter
    Till, Brian G.
    Gopal, Ajay K.
    Maloney, David G.
    Turtle, Cameron J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S112 - S113
  • [28] CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma
    Siddiqi, Tanya
    Wang, Xiuli
    Palmer, Joycelynne
    Popplewell, Leslie L.
    Nikolaenko, Liana
    Herrera, Alex F.
    Budde, Lihua E.
    Lim, Laura
    Vyas, Vibhuti
    Brown, Christine E.
    Forman, Stephen J.
    BLOOD, 2019, 134
  • [29] Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed BCell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy
    Yang, Fan
    Liu, Rui
    Xu, Teng
    Zheng, Peihao
    Feng, Shaomei
    Guo, Yuelu
    Ma, Lixia
    Shi, Hui
    Deng, Biping
    Ke, Xiaoyan
    Wu, Tong
    Hu, Kai
    BLOOD, 2022, 140 : 10384 - 10385
  • [30] CD19-Targeting CAR T-Cell Therapy for Antisynthetase Syndrome
    Lundberg, Ingrid E.
    Galindo-Feria, Angeles S.
    Horuluoglu, Begum
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (24): : 2130 - 2131
12345